Literature DB >> 9590145

Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia.

M K Horne1, K J Hutchison.   

Abstract

Heparin-induced thrombocytopenia (HIT) is mediated by antibody against complexes of platelet factor-4 (PF4) and heparin. Although it has been assumed that these complexes bind to platelets and provide a target for the antibody, this has never been demonstrated. Furthermore, there is evidence suggesting that heparin-PF4 complexes do not bind to platelets. We have analyzed the effect of each ligand on the platelet binding of the other. We particularly focused on the result when heparin and PF4 are in equimolar concentration because we had previously shown that this was the condition under which HIT-IgG increased on the platelet surface. We found that when the molar concentration of PF4 approximates or exceeds that of heparin, the ligands bind simultaneously to the cells and HIT-IgG binds also. However, when heparin is in molar excess, both PF4 binding and HIT-IgG binding are diminished. Our data are consistent with the hypothesis that heparin-PF4 complexes bind via their heparin component to heparin binding sites on the platelet membrane rather than by their PF4 component to PF4 sites. The conditions promoting the binding of the complexes also lead to binding of HIT-IgG.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590145     DOI: 10.1002/(sici)1096-8652(199805)58:1<24::aid-ajh5>3.0.co;2-2

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  Heparin resistance in acute coronary syndromes.

Authors:  Jonathan D Rich; John M Maraganore; Edward Young; Rosa-Maria Lidon; Burt Adelman; Paul Bourdon; Supoat Charenkavanich; Jack Hirsh; Pierre Theroux; Christopher P Cannon
Journal:  J Thromb Thrombolysis       Date:  2007-01-13       Impact factor: 2.300

2.  Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.

Authors:  Lubica Rauova; Li Zhai; M Anna Kowalska; Gowthami M Arepally; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

Review 3.  Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia.

Authors:  J M Walenga; W P Jeske; H L Messmore
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

4.  Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.

Authors:  Anand Padmanabhan; Curtis G Jones; Daniel W Bougie; Brian R Curtis; Janice G McFarland; Demin Wang; Richard H Aster
Journal:  Blood       Date:  2014-10-23       Impact factor: 22.113

5.  Effect of 6-O-sulfonate hexosamine residue on anticoagulant activity of fully O-sulfonated glycosaminoglycans.

Authors:  T Toida; A Suzuki; K Nakajima; A Chaidedgumjorn; T Imanari
Journal:  Glycoconj J       Date:  2000-06       Impact factor: 2.916

6.  Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling.

Authors:  Cunji Gao; Brian Boylan; Juan Fang; David A Wilcox; Debra K Newman; Peter J Newman
Journal:  Blood       Date:  2011-03-02       Impact factor: 22.113

7.  Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.

Authors:  Zhihua Xiao; Gian P Visentin; Kannayakanahalli M Dayananda; Sriram Neelamegham
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

8.  Update on the safety and bioequivalence of biosimilars - focus on enoxaparin.

Authors:  Walter Jeske; Jeanine M Walenga; Debra Hoppensteadt; Jawed Fareed
Journal:  Drug Healthc Patient Saf       Date:  2013-06-10

9.  Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia.

Authors:  Navdeep Singh; Sandeep Singh Lubana; Han-Mou Tsai
Journal:  Am J Case Rep       Date:  2020-05-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.